Brief: Medigene Says Its PD1-41BB Switch Receptor Improves Tcr-T Cell Functionality
16/09/2021 08:12
Sept 16 (Reuters) - MEDIGENE AG MDG1k.DE :
* PMEDIGENE'S PD1-41BB SWITCH RECEPTOR IMPROVES TCR-T CELL
FUNCTIONALITY AGAINST SOLID TUMORS
Source text for Eikon: ID:nPexzgsNQa
Further company coverage: MDG1k.DE
(Gdansk Newsroom)
((Gdansk.Newsroom@thomsonreuters.com;))
Recent news on Medigene AG
See all newsBrief: Medigene Files Application For The Opening Of Insolvency Proceedings
Brief: Medigene Files Patent For Unique Nk-Specific TCR Construct With European Patent Office
Brief: Medigene AG Says Co Amends Financial Guidance For 2024
Brief: Medigene AG Expands Protection Of KRAS Library With Filing Of New Patent Application
Brief: Medigene H1 Revenue EUR 4.5 Million